Hemofarm is one of the leading pharmaceutical companies in Serbia and the region, and since 2006 it has been part of the German STADA Group, one of the world's largest generic pharmaceutical companies. The primary activity of the company is the production of quality, efficient, safe and available pharmaceutical products.

At the #QasConcept2018 Conference, Miloš Puzić, Head of Hemofarm Maintenance, spoke about the application of the FMEA (Failure Mode and Effects Analysis) tools in the process of supplier evaluation.

 

 

FMEA is a tool that identifies and analyzes possible (or specific-predefined) failure modes, follows how failure is performed and analyzes the associated risks to the process or product. FMEA systemically enables to establish the actions to eliminate or significantly reduce the associated risks. Although the tool is most often used in the phase analysis of DMAIC (LSS) projects, FMEA can be used successfully as part of a routine process. One such example is the supplier evaluation process. In addition to the short theoretical introduction with the FMEA tool, an example from the practice is presented where, in order to uncover the nonconformity at one stage of the production process, an evaluation of the production processes of the packaging suppliers occurred.

Hemofarm's vision is to be a leading health care company. In order to achieve this, the organization employs many knowledge and uses the tools and models that lead to continuous improvement on a daily basis.

 

Share this video with anyone you think would benefit from understanding how FMEA tools can identify potentially risky phases of the production processes in practice.